Canada markets closed

VYNE Therapeutics Inc. (VYNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.6200+0.1200 (+4.80%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 36.94M
Enterprise Value -56.10M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)63.48
Price/Book (mrq)0.42
Enterprise Value/Revenue -132.31
Enterprise Value/EBITDA 1.92

Trading Information

Stock Price History

Beta (5Y Monthly) 1.46
52-Week Change 3-71.13%
S&P500 52-Week Change 322.38%
52 Week High 38.7300
52 Week Low 31.6700
50-Day Moving Average 32.4633
200-Day Moving Average 33.0915

Share Statistics

Avg Vol (3 month) 3103.58k
Avg Vol (10 day) 372.67k
Shares Outstanding 514.1M
Implied Shares Outstanding 614.1M
Float 89.45M
% Held by Insiders 18.69%
% Held by Institutions 159.21%
Shares Short (Apr 15, 2024) 496.83k
Short Ratio (Apr 15, 2024) 40.59
Short % of Float (Apr 15, 2024) 40.69%
Short % of Shares Outstanding (Apr 15, 2024) 40.69%
Shares Short (prior month Mar 15, 2024) 412.44k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:18
Last Split Date 3Feb 13, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-8,989.47%

Management Effectiveness

Return on Assets (ttm)-26.42%
Return on Equity (ttm)-46.40%

Income Statement

Revenue (ttm)424k
Revenue Per Share (ttm)0.04
Quarterly Revenue Growth (yoy)1,166.70%
Gross Profit (ttm)N/A
EBITDA -29.19M
Net Income Avi to Common (ttm)-28.02M
Diluted EPS (ttm)-2.7200
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)93.25M
Total Cash Per Share (mrq)6.61
Total Debt (mrq)214k
Total Debt/Equity (mrq)0.24%
Current Ratio (mrq)12.73
Book Value Per Share (mrq)6.29

Cash Flow Statement

Operating Cash Flow (ttm)-25.34M
Levered Free Cash Flow (ttm)-12.25M